person · Reporting owner

Popovits Kimberly J

Disclosed activity across 8 companies

Tapewire entity: 36274
SEC CIK: 0001333482

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
10x Genomics, Inc.TXG · Entity 2172	Director	June 04, 2026	June 08, 2026
Kardigan, Inc.KARD · Entity 4569	Director	June 17, 2026	June 22, 2026
Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954	Director	May 29, 2026	June 02, 2026
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693	Director	April 01, 2026	April 03, 2026
Talis Biomedical CorpTLIS · Entity 87664	Director	June 09, 2023	June 12, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

10x Genomics, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	37,445	Reported balance After 2026-06-04 transaction · row 1 1 source row Row 1 · 2026-06-04 · Grant · Acquired 8,829 · Balance 37,445 F1: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Kardigan, Inc.

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,706	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 20,706 · Balance 20,706 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Kiniksa Pharmaceuticals International, plc

Report date May 29, 2026 · Filed June 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary ShareSEC Table I · non-derivative	Direct	15,345	Reported balance After 2026-05-29 transaction · row 1 1 source row Row 1 · 2026-05-29 · Exercise / conversion · Acquired 2,799 · Balance 15,345 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.38 · Expires 2036-05-28	Direct	12,158	Reported balance After 2026-05-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-29 · Grant · Acquired 12,158 · Balance 12,158 F2: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	2,026	Reported balance After 2026-05-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-29 · Grant · Acquired 2,026 · Balance 2,026 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-29 · Exercise / conversion · Disposed 2,799 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F2: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

F3: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

F4: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

RHYTHM PHARMACEUTICALS, INC.

Report date April 01, 2026 · Filed April 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	6,808	Reported balance After 2026-04-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-01 · Grant · Acquired 6,808 · Balance 6,808 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units will vest as to 33% of the total shares on each of April 1, 2027, April 1, 2028, April 1, 2029. The restricted stock units have no expiration date.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.12 · Expires 2036-03-31	Direct	10,257	Reported balance After 2026-04-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-01 · Grant · Acquired 10,257 · Balance 10,257 F3: The stock options were granted on April 1, 2026. The options vest and become exercisable in three substantially equal annual installments subject to the Reporting Person continuing in service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2: The restricted stock units will vest as to 33% of the total shares on each of April 1, 2027, April 1, 2028, April 1, 2029. The restricted stock units have no expiration date.

F3: The stock options were granted on April 1, 2026. The options vest and become exercisable in three substantially equal annual installments subject to the Reporting Person continuing in service through each such vesting date.

Talis Biomedical Corp

Report date June 09, 2023 · Filed June 12, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-09	Direct	95,000	Reported balance After 2023-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-09 · Grant · Acquired 95,000 · Balance 95,000 F1: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

EXACT SCIENCES CORP

Report date March 23, 2026 · Filed March 23, 2026

Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2026-03-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-03-23 · Disposition to issuer · Disposed 6,725 · Balance 9,656 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Row 2 · 2026-03-23 · Disposition to issuer · Disposed 9,656 · Balance 0 F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

Filing footnotes · ownership attribution and instrument terms

F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").

F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

GENOMIC HEALTH INC

Report date November 08, 2019 · Filed November 14, 2019

Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHeld by Morgan Stanley as Custodian for Benefit of Kimberly Popovits	0	Reported balance After 2019-11-08 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-11-08 · Disposition to issuer · Disposed 12,298 · Balance 0 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences,Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $338,229 and 5,539 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Common StockSEC Table I · non-derivative	IndirectHeld by the Popovits 2010 Trust	0	Reported balance After 2019-11-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-11-08 · Disposition to issuer · Disposed 68,268 · Balance 0 F2: Disposed of in connection with the Merger, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $1,877,453 and 30,749 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-11-08 transaction · row 3 1 source row Row 3 · 2019-11-08 · Disposition to issuer · Disposed 36,168 · Balance 0 F3: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit ("RSU") was assumed by Exact Sciences and converted into a corresponding award for 27,680 RSUs of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.05 · Expires 2023-01-31	Direct	0	Reported balance After 2019-11-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-08 · Disposition to issuer · Disposed 67,500 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $1,077,212, less applicable tax withholdings, and 17,643 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.84 · Expires 2024-01-28	Direct	0	Reported balance After 2019-11-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-08 · Disposition to issuer · Disposed 100,000 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $1,481,074, less applicable tax withholdings, and 24,258 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2026-02-16	Direct	12,822	Reported balance After 2019-11-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-08 · Disposition to issuer · Disposed 141,038 · Balance 12,822 F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $2,311,715, less applicable tax withholdings, and 37,864 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2026-02-16	Direct	0	Reported balance After 2019-11-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-08 · Disposition to issuer · Disposed 12,822 · Balance 0 F7: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 9,813 shares of Exact Sciences common stock with an exercise price of $35.28 per share.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.48 · Expires 2027-01-31	Direct	59,844	Reported balance After 2019-11-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-08 · Disposition to issuer · Disposed 131,656 · Balance 59,844 F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $2,131,936, less applicable tax withholdings, and 34,919 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $27.48 · Expires 2027-01-31	Direct	0	Reported balance After 2019-11-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-11-08 · Disposition to issuer · Disposed 59,844 · Balance 0 F9: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 45,800 shares of Exact Sciences common stock with an exercise price of $35.91 per share.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $33.21 · Expires 2028-01-31	Direct	92,869	Reported balance After 2019-11-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-11-08 · Disposition to issuer · Disposed 72,231 · Balance 92,869 F10: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $999,359, less applicable tax withholdings, and 16,368 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $33.21 · Expires 2028-01-31	Direct	0	Reported balance After 2019-11-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-11-08 · Disposition to issuer · Disposed 92,869 · Balance 0 F11: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 71,075 shares of Exact Sciences common stock with an exercise price of $43.40 per share.
Employee Stock Option (right to buy) HoldingSEC Table II · derivative / convertible security · Conversion / exercise price $72.52 · Expires 2029-01-29	Direct	0	Reported balance After 2019-11-08 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-11-08 · Disposition to issuer · Disposed 75,610 · Balance 0 F12: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 57,866 shares of Exact Sciences common stock with an exercise price of $94.76 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences,Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $338,229 and 5,539 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F2: Disposed of in connection with the Merger, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $1,877,453 and 30,749 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F3: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit ("RSU") was assumed by Exact Sciences and converted into a corresponding award for 27,680 RSUs of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $1,077,212, less applicable tax withholdings, and 17,643 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $1,481,074, less applicable tax withholdings, and 24,258 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $2,311,715, less applicable tax withholdings, and 37,864 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F7: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 9,813 shares of Exact Sciences common stock with an exercise price of $35.28 per share.

F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $2,131,936, less applicable tax withholdings, and 34,919 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F9: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 45,800 shares of Exact Sciences common stock with an exercise price of $35.91 per share.

F10: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $999,359, less applicable tax withholdings, and 16,368 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F11: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 71,075 shares of Exact Sciences common stock with an exercise price of $43.40 per share.

F12: Disposed of in connection with the Merger, whereby such Issuer stock option was assumed by Exact Sciences and converted into a corresponding award for an option to purchase 57,866 shares of Exact Sciences common stock with an exercise price of $94.76 per share.

MyoKardia, Inc.

Report date November 17, 2020 · Filed November 20, 2020

Section 16 reporting ended · disclosed 2020-11-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-11-17 transaction · row 1 1 source row Row 1 · 2020-11-17 · Other · Disposed 4,100 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.35	Direct	Reported balance After 2020-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-17 · Disposition to issuer · Disposed 22,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00	Direct	Reported balance After 2020-11-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.85	Direct	Reported balance After 2020-11-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.77	Direct	Reported balance After 2020-11-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-17 · Disposition to issuer · Disposed 6,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.27	Direct	Reported balance After 2020-11-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-17 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 17, 2026 Filed Jun 22, 2026 23:19 UTC	Kardigan, Inc. KARD · Entity 4569	GrantCommon Stock	20,706	$0.00	$0.00	Disclosure SEC source: 0001193125-26-277921 · ownership.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,706 F1 · kind: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date. Read SEC document
June 04, 2026 Filed Jun 8, 2026 23:25 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantClass A Common Stock	8,829	$0.00	$0.00	Disclosure SEC source: 0001610717-26-000193 · form4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,445 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:51 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionRestricted Share Units · Derivative	2,799	$0.00	$0.00	Disclosure SEC source: 0001333482-26-000002 · form4-06022026_080611.xml · derivative · entry 4 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 2,799 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:51 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantRestricted Share Units · Derivative	2,026	$0.00	$0.00	Disclosure SEC source: 0001333482-26-000002 · form4-06022026_080611.xml · derivative · entry 3 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,026 Underlying: Class A Ordinary Shares · 2,026 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:51 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantShare Option · Derivative	12,158	$0.00 Strike: $48.38	$0.00	Disclosure SEC source: 0001333482-26-000002 · form4-06022026_080611.xml · derivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,158 Underlying: Class A Ordinary Shares · 12,158 shares Expires 2036-05-28 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:51 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionClass A Ordinary Share	2,799	Not disclosed	Not disclosed	Disclosure SEC source: 0001333482-26-000002 · form4-06022026_080611.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document
April 01, 2026 Filed Apr 3, 2026 21:35 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantStock Options (Right to Buy) · Derivative	10,257	$0.00 Strike: $88.12	$0.00	Disclosure SEC source: 0001104659-26-039685 · tm2611099-2_4seq1.xml · derivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,257 Underlying: Common Stock · 10,257 shares Expires 2036-03-31 F3 · derivative.exercise_date: The stock options were granted on April 1, 2026. The options vest and become exercisable in three substantially equal annual installments subject to the Reporting Person continuing in service through each such vesting date. Read SEC document
April 01, 2026 Filed Apr 3, 2026 21:35 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantRestricted Stock Units · Derivative	6,808	$0.00	$0.00	Disclosure SEC source: 0001104659-26-039685 · tm2611099-2_4seq1.xml · derivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,808 Underlying: Common Stock · 6,808 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest as to 33% of the total shares on each of April 1, 2027, April 1, 2028, April 1, 2029. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units will vest as to 33% of the total shares on each of April 1, 2027, April 1, 2028, April 1, 2029. The restricted stock units have no expiration date. Read SEC document
March 23, 2026 Filed Mar 23, 2026 09:18 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Disposition to issuerCommon Stock	9,656	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-118745 · ownership.xml · nonDerivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding. Read SEC document
March 23, 2026 Filed Mar 23, 2026 09:18 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Disposition to issuerCommon Stock	6,725	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-118745 · ownership.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,656 F1 · price: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Read SEC document
July 30, 2025 Filed Aug 1, 2025 20:36 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionShare Option · Derivative	18,760	$0.00 Strike: $15.47	$0.00	Disclosure SEC source: 0001415889-25-020866 · form4-08012025_080803.xml · derivative · entry 5 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 18,760 shares Expires 2029-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
July 30, 2025 Filed Aug 1, 2025 20:36 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionShare Option · Derivative	45,748	$0.00 Strike: $10.36	$0.00	Disclosure SEC source: 0001415889-25-020866 · form4-08012025_080803.xml · derivative · entry 4 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 45,748 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
July 30, 2025 Filed Aug 1, 2025 20:36 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionClass A Ordinary Share	64,508	$29.90	$1,928,789.20	Disclosure SEC source: 0001415889-25-020866 · form4-08012025_080803.xml · nonDerivative · entry 3 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $29.66 and $30.07. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document
July 30, 2025 Filed Aug 1, 2025 20:36 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionClass A Ordinary Share	18,760	$15.47	$290,217.20	Disclosure SEC source: 0001415889-25-020866 · form4-08012025_080803.xml · nonDerivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 30, 2025 Filed Aug 1, 2025 20:36 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionClass A Ordinary Share	45,748	$10.36	$473,949.28	Disclosure SEC source: 0001415889-25-020866 · form4-08012025_080803.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 12, 2025 Filed Jun 16, 2025 17:30 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	9,994	$0.00	$0.00	Disclosure SEC source: 0000950170-25-086888 · ownership.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,381 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document
June 05, 2025 Filed Jun 5, 2025 20:55 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionRestricted Share Units · Derivative	3,173	$0.00	$0.00	Disclosure SEC source: 0001415889-25-015788 · form4-06052025_080613.xml · derivative · entry 4 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 3,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs. Read SEC document
June 05, 2025 Filed Jun 5, 2025 20:55 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionClass A Ordinary Share	3,173	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-015788 · form4-06052025_080613.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:55 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantRestricted Share Units · Derivative	2,799	$0.00	$0.00	Disclosure SEC source: 0001415889-25-015788 · form4-06052025_080613.xml · derivative · entry 3 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,799 Underlying: Class A Ordinary Shares · 2,799 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:55 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantShare Option · Derivative	16,798	$0.00 Strike: $29.11	$0.00	Disclosure SEC source: 0001415889-25-015788 · form4-06052025_080613.xml · derivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,798 Underlying: Class A Ordinary Shares · 16,798 shares Expires 2035-06-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. Read SEC document
June 03, 2025 Filed Jun 5, 2025 21:21 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantClass A Common Stock	15,357	$0.00	$0.00	Disclosure SEC source: 0001610717-25-000169 · form4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,616 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2025, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
January 02, 2025 Filed Jan 6, 2025 16:12 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	6,387	$0.00	$0.00	Disclosure SEC source: 0000950170-25-002084 · ownership.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,387 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy and vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 11, 2024 Filed Jun 13, 2024 20:24 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantClass A Common Stock	8,649	$0.00	$0.00	Disclosure SEC source: 0001610717-24-000328 · form4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,259 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2024, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 06, 2024 Filed Jun 7, 2024 20:36 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionRestricted Share Units · Derivative	4,373	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015997 · form4-06072024_080618.xml · derivative · entry 4 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 4,373 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs. Read SEC document
June 06, 2024 Filed Jun 7, 2024 20:36 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionClass A Common Share	4,373	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-015997 · form4-06072024_080618.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:36 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantRestricted Share Units · Derivative	3,173	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015997 · form4-06072024_080618.xml · derivative · entry 3 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,173 Underlying: Class A Common Shares · 3,173 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024. Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:36 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantShare Option · Derivative	19,040	$0.00 Strike: $19.71	$0.00	Disclosure SEC source: 0001415889-24-015997 · form4-06072024_080618.xml · derivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,040 Underlying: Class A Common Shares · 19,040 shares Expires 2034-06-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 5, 2024. Read SEC document
June 29, 2023 Filed Jul 3, 2023 20:15 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionRestricted Share Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001415889-23-010561 · form4-07032023_040706.xml · derivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs. Read SEC document
June 29, 2023 Filed Jul 3, 2023 20:15 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	Exercise / conversionClass A Common Share	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-23-010561 · form4-07032023_040706.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:41 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantStock Option (right to buy) · Derivative	4,661	$0.00 Strike: $57.62	$0.00	Disclosure SEC source: 0001610717-23-000174 · form4.xml · derivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,661 Underlying: Class A Common Stock · 4,661 shares Expires 2033-06-14 F2 · derivative.exercise_date: 1/12th of the total number of shares subject to the option vest on each monthly anniversary measured from June 14, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 14, 2023 Filed Jun 16, 2023 21:41 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantClass A Common Stock	1,865	$0.00	$0.00	Disclosure SEC source: 0001610717-23-000174 · form4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,610 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 09, 2023 Filed Jun 12, 2023 21:26 UTC	Talis Biomedical Corp TLIS · Entity 87664	GrantStock option (right to buy) · Derivative	95,000	$0.00 Strike: $0.50	$0.00	Disclosure SEC source: 0001209191-23-036398 · doc4.xml · derivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2033-06-09 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date. Read SEC document
June 06, 2023 Filed Jun 8, 2023 20:22 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantRestricted Share Units · Derivative	4,373	$0.00	$0.00	Disclosure SEC source: 0001415889-23-009429 · form4-06082023_080635.xml · derivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,373 Underlying: Class A Common Shares · 4,373 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023. Read SEC document
June 06, 2023 Filed Jun 8, 2023 20:22 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantShare Option · Derivative	26,236	$0.00 Strike: $15.19	$0.00	Disclosure SEC source: 0001415889-23-009429 · form4-06082023_080635.xml · derivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,236 Underlying: Class A Common Shares · 26,236 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023. Read SEC document
June 29, 2022 Filed Jun 30, 2022 20:18 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantRestricted Share Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001415889-22-007104 · form4-06302022_010644.xml · derivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Class A Common Shares · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. Read SEC document
June 29, 2022 Filed Jun 30, 2022 20:18 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantShare Option · Derivative	30,000	$0.00 Strike: $9.88	$0.00	Disclosure SEC source: 0001415889-22-007104 · form4-06302022_010644.xml · derivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Shares · 30,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2022. Read SEC document
June 15, 2022 Filed Jun 17, 2022 21:24 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantStock Option (right to buy) · Derivative	5,300	$0.00 Strike: $39.62	$0.00	Disclosure SEC source: 0001567619-22-013122 · doc1.xml · derivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Class A Common Stock · 5,300 shares Expires 2032-06-15 F2 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one-twelfth of the shares on July 15, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 15, 2022 Filed Jun 17, 2022 21:24 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantClass A Common Stock	2,120	$0.00	$0.00	Disclosure SEC source: 0001567619-22-013122 · doc1.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,745 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-fourth of the RSUs, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, shall vest on August 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 10, 2022 Filed Jun 13, 2022 21:39 UTC	Talis Biomedical Corp TLIS · Entity 87664	GrantStock Option (right to buy) · Derivative	95,000	$0.00 Strike: $1.00	$0.00	Disclosure SEC source: 0001209191-22-036423 · doc4.xml · derivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date. Read SEC document
August 30, 2021 Filed Sep 1, 2021 01:01 UTC	Talis Biomedical Corp TLIS · Entity 87664	GrantStock Option (right to buy) · Derivative	550,000	$0.00 Strike: $9.06	$0.00	Disclosure SEC source: 0001209191-21-054181 · doc4.xml · derivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2031-08-29 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date. Read SEC document
June 29, 2021 Filed Jun 30, 2021 20:22 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantShare Option · Derivative	33,237	$0.00 Strike: $14.33	$0.00	Disclosure SEC source: 0001179110-21-007185 · edgar.xml · derivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,237 Underlying: Class A Common Shares · 33,237 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2021. Read SEC document
June 11, 2021 Filed Jun 15, 2021 21:51 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantStock Option (right to buy) · Derivative	1,563	$0.00 Strike: $193.51	$0.00	Disclosure SEC source: 0001209191-21-040690 · doc4.xml · derivative · entry 2 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,563 Underlying: Class A Common Stock · 1,563 shares Expires 2031-06-11 F2 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one-twelfth of the shares on July 11, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 11, 2021 Filed Jun 15, 2021 21:51 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantClass A Common Stock	625	$0.00	$0.00	Disclosure SEC source: 0001209191-21-040690 · doc4.xml · nonDerivative · entry 1 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-fourth of the RSUs, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, shall vest on August 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:21 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionSeries F-1 Preferred Stock · Derivative	128,655	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012522 · doc4.xml · derivative · entry 9 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By MSL FBO Kimberly J. Popovits Patrick J. Popovits TTEE U/A/D 05- 17-2010 FBO Popovits 2010 Trust Disclosed balance after: 0 Underlying: Common Stock · 89,968 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series F-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series F-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series F-1 Preferred Stock. F4 · derivative.exercise_date: Each share of Series F-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series F-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series F-1 Preferred Stock. F4 · derivative.expiration_date: Each share of Series F-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series F-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series F-1 Preferred Stock. F3 · ownership.nature: Ms. Popovits and her spouse are trustees of the MSL FBO Kimberly J. Popovits Patrick J. Popovits TTEE U/A/D 05-17-2010 FBO Popovits 2010 Trust and share voting and dispositive power. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:21 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionSeries E-1 Preferred Stock · Derivative	131,642	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012522 · doc4.xml · derivative · entry 8 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By MSL FBO Kimberly J. Popovits Patrick J. Popovits TTEE U/A/D 05- 17-2010 FBO Popovits 2010 Trust Disclosed balance after: 0 Underlying: Common Stock · 92,057 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock. F2 · derivative.exercise_date: Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock. F2 · derivative.expiration_date: Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock. F3 · ownership.nature: Ms. Popovits and her spouse are trustees of the MSL FBO Kimberly J. Popovits Patrick J. Popovits TTEE U/A/D 05-17-2010 FBO Popovits 2010 Trust and share voting and dispositive power. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:21 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionSeries E-1 Preferred Stock · Derivative	300,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012522 · doc4.xml · derivative · entry 7 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common Stock · 209,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock. F2 · derivative.exercise_date: Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock. F2 · derivative.expiration_date: Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:21 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionSeries C-1 Preferred Stock · Derivative	31,519	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012522 · doc4.xml · derivative · entry 6 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series C-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series C-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series C-1 Preferred Stock. F1 · derivative.exercise_date: Each share of Series C-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series C-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series C-1 Preferred Stock. F1 · derivative.expiration_date: Each share of Series C-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series C-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series C-1 Preferred Stock. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:21 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionCommon Stock	89,968	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012522 · doc4.xml · nonDerivative · entry 5 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By MSL FBO Kimberly J. Popovits Patrick J. Popovits TTEE U/A/D 05- 17-2010 FBO Popovits 2010 Trust Disclosed balance after: 182,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series F-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series F-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series F-1 Preferred Stock. F3 · ownership.nature: Ms. Popovits and her spouse are trustees of the MSL FBO Kimberly J. Popovits Patrick J. Popovits TTEE U/A/D 05-17-2010 FBO Popovits 2010 Trust and share voting and dispositive power. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:21 UTC	Talis Biomedical Corp TLIS · Entity 87664	ConversionCommon Stock	92,057	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012522 · doc4.xml · nonDerivative · entry 4 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By MSL FBO Kimberly J. Popovits Patrick J. Popovits TTEE U/A/D 05- 17-2010 FBO Popovits 2010 Trust Disclosed balance after: 92,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series E-1 Preferred Stock automatically converts on a 1-for-1.43 basis into Common Stock at any time at the holder's election and has no expiration date. At the closing of the Issuer's initial public offering, each share of Series E-1 Preferred stock converted into shares of Common Stock, for no additional consideration, at a rate of one share of Common Stock for each 1.43 shares of Series E-1 Preferred Stock. F3 · ownership.nature: Ms. Popovits and her spouse are trustees of the MSL FBO Kimberly J. Popovits Patrick J. Popovits TTEE U/A/D 05-17-2010 FBO Popovits 2010 Trust and share voting and dispositive power. Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:21 UTC	Talis Biomedical Corp TLIS · Entity 87664	PurchaseCommon Stock	5,300	$16.00	$84,800.00	Disclosure SEC source: 0001209191-21-012522 · doc4.xml · nonDerivative · entry 3 Popovits Kimberly J · CIK 0001333482 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 215,090 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.